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NOTES FROM THE FIELD 
Working to Improve Human Papilloma Virus Vaccination Uptake in Michigan 
 
Courtney Cole, Michigan Public Health Institute, Angela McFall, Michigan Department of 
Health and Human Services 
 
The human papilloma virus (HPV) is a known carcinogen that causes most cervical cancers, as 
well as some cancers of the vagina, vulva, penis, anus, rectum, and oropharynx (Centers for 
Disease Control and Prevention [CDC], 2018). In Michigan, from 2010 – 2014, 1,314 people 
were diagnosed with HPV associated cancers (CDC, 2018). When identifying cancer prevention 
strategies to incorporate in the continuum of care, secondary prevention methods are the most 
common, and include cancer screenings, early detection, and progressive treatment. Vaccinations 
serve as a primary prevention method and the Food and Drug Administration (FDA) approved 
HPV Vaccine, reduces the incidence of cancer and the frequency of the virus. One of the Healthy 
People 2020 objectives is to achieve a HPV vaccine completion rate of 80% for males and 
females. Implementation of HPV evidence-based interventions and health education initiatives 
are imperative to achieve this goal.  
 
In Michigan, HPV vaccine initiation and completion rates among adolescents aged 13-17 years 
old is less than 50% (MCIR, 2018). According to researchers, identified barriers associated with 
low HPV vaccine uptake include provider hesitancy, vaccine stigma, and low uptake amongst 
the male population (Southall, 2016). In the statewide Cancer Plan for Michigan 2016-2020, the 
reduction of cervical cancer through the increase in HPV vaccination is by 2020 to: 
 
Increase the proportion of females and males ages 13-17 years who have received at least 
three doses of HPV vaccine from 24.2% (females) and 7.4% (males) to 80% (females and 
males). 
 
The Michigan Cancer Consortium (MCC) Board of Directors selected this objective as one of 
four priorities for 2016-2017, thus the MCC HPV Vaccine Priority Workgroup was assembled. 
Upon examining the data, the priority workgroup members decided to focus the work plan on 
increasing HPV vaccinations in the Hispanic population in Michigan. The work plan for the 
HPV Vaccine Priority Workgroup included conducting focus groups with the Hispanic 
population to gauge HPV and cervical cancer specific knowledge and reactions to three 
advertisements about the HPV vaccine.  
 
Focus group findings revealed women were the primary health care decision makers of the 
family and reported more sources of health information than their male counterparts. Sources of 
health information included physician contact, online health resources, friends, and family 
members. Specifically, women were interested in acquiring accurate information about the HPV 
vaccine related to dosing and age recommendations and were not aware that the vaccine could 
benefit boys as well as girls. The male focus group reported being unaware of the HPV and its 
effects on the male population. Both focus groups identified a need for Spanish language 
materials about HPV. Important aspects of communicating about HPV vaccination included 
addressing the parents, having a direct message, and making the information relatable to the 
Latino community.  
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The focus group outcomes resulted in translation of HPV public service announcements and an 
educational brochure into Spanish. A multi-media campaign using these materials was 
conducted. The campaign included radio ads on Spanish stations in Grand Rapids, Kalamazoo, 
and Big Rapids, as well as print ads in the Spanish language newspaper, Lazo Cultural. The 
MCC website includes the Spanish language resources developed during this project.  
In 2017, the HPV cancer plan objective was updated to incorporate new recommendations 
delineated by the CDC concerning dosing. In October of 2016 the CDC began recommending 2 
doses of HPV vaccine for people starting the vaccination series before their 15th birthday rather 
than the previously recommended 3 dose series. Three doses are still recommended for people 
over the age of 15 or those with immunocompromising conditions to combat cancers associated 
with HPV infections (CDC, 2016). The updated project objective is by 2020 to: 
  
Increase the proportion of females and males ages 13-17 years who have completed the 
recommended series of HPV vaccine to 80%.  
 
With the 2016-2017 project complete, the HPV Vaccine Workgroup developed a project work 
plan for 2018-2019. This work plan utilizes the CDC’s AFIX (Assessment, Feedback, Incentives, 
and eXchange) model to evaluate provider performance in offering and administering the HPV 
vaccine to clients 9-26 years old according to the current recommended vaccine schedule in five 
regions of the state. Efforts are already underway to implement the new work plan.  
This publication was supported by the Cooperative Agreement NU58DP006334 from the Centers for Disease 
Control and Prevention.  Its contents are solely the responsibility of the authors and do not necessarily 
represent the official views of the Centers for Disease Control and Prevention. 
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